Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to better understand brain tumors known as glioblastomas, specifically how they behave in terms of metabolism. Researchers will use advanced imaging techniques, including special scans called PET and MRI, to study the differences in how glioblastoma tumors absorb certain substances. These scans will help them compare the tumor's metabolism in patients who are newly diagnosed with glioblastoma and those whose tumors have returned after treatment. The goal is to gather important information that could improve future treatment options.

To participate in this study, individuals must be at least 18 years old and have a diagnosis of glioblastoma, either as a new case or a recurrence. They should be recommended for surgery and have a life expectancy of more than three months. Participants will undergo various imaging tests, and their overall health will be monitored throughout the study. It’s important to note that only individuals who can fully understand and agree to be part of the study will be approached, and there are some health conditions that may prevent participation. If you or a loved one is considering taking part, you'll receive detailed information and support before making any decisions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants will be ≥ 18 years of age
• Must meet the following criteria:
• • -Diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist.
• • OR
• • New contrast-enhancing lesion or lesions showing increased enhancement (\>25%increase) in a patient with a historical diagnosis of glioblastoma (histologic or molecular proof) on standard MRI after completion of treatment
• • Recommended for clinically indicated surgical resection
• • Life expectancy of greater than 3 months in the opinion of an investigator or treating physician.
• • Karnofsky performance status ≥ 60 per medical record review
• • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Exclusion Criteria:
• • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• • Females who are pregnant or breastfeeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential prior to injection.
• • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
• • Contraindications to MRI
• • Only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study